Hormone-receptor positive breast cancer: highlights from the 39TH San Antonio Breast Cancer Symposium

Giorgia Zucchini, Filippo Montemurro

Research output: Contribution to journalArticlepeer-review


The San Antonio Breast Cancer Symposium is considered one of the most influential international meetings focusing on breast cancer management, covering several areas of study from basic research to clinical practice topics. a number of oral presentations addressing hormone receptor-positive breast cancer brought new data about critical subjects like the optimal duration of adjuvant endocrine therapy, new prognostic markers and their potential role in guiding adjuvant treatment choices, new insights into genomic alterations acquired during the metastatic process, and pharmacologic strategies to overcome resistance to endocrine therapy. This article aims at summarizing some of the presentations that, in our opinion, are expected to have an impact on clinical practice and research programs in this patient population.

Original languageEnglish
Pages (from-to)853-855
Number of pages3
JournalExpert Opinion on Pharmacotherapy
Issue number9
Publication statusPublished - Jun 13 2017


  • aromatase inhibitors
  • buparlisib
  • endocrine therapy
  • everolimus
  • fulvestrant
  • gene-expression analysis
  • genomic alterations
  • Hormone-receptor
  • tamoxifen

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)


Dive into the research topics of 'Hormone-receptor positive breast cancer: highlights from the 39TH San Antonio Breast Cancer Symposium'. Together they form a unique fingerprint.

Cite this